Hi Dr. Kim, just wanted to thank you for these short videos. I'm a medical oncology resident prepping for my exam in a few weeks. These videos provide a great summary for me and helps me know where to dive into more details on. Really appreciate it, wishing you all the best!
The US Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) in combination with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma. The approval was based on findings from the randomized, controlled, open-label NAPOLI3 trial, which evaluated the combination, known as NALIRIFOX, vs gemcitabine plus nab-paclitaxel in patients who had not previously received chemotherapy in the metastatic setting. The National Comprehensive Cancer Network also upgraded the regimen as the preferred first-line treatment for metastatic pancreatic adenocarcinoma as well as for locally advanced disease. clinicaltrials.gov/study/NCT04083235 In the trial, 770 patients were randomized 1:1 to receive NALIRIFOX or gemcitabine plus nab-paclitaxel, a current standard of care in this setting. Patients receiving NALIRIFOX demonstrated significant improvements in median overall survival and progression-free survival (PFS) - with a median overall survival of 11.1 months vs 9.2 months in the gemcitabine plus nab-paclitaxel arm (hazard ratio [HR], 0.84) and a median PFS of 7.4 months vs 5.6 months (HR, 0.70). The overall response rate was also higher in the NALIRIFOX arm - 41.8% vs 36.2%. The recommended irinotecan liposome dose is 50 mg/m2 administered by intravenous infusion over 90 minutes every 2 weeks, before oxaliplatin, fluorouracil, and leucovorin. There is no recommended irinotecan liposome dose for patients with serum bilirubin above the upper limit of normal. The label for irinotecan liposome comes with a boxed warning, noting a risk for severe or life-threatening neutropenia and diarrhea.
Excellent update. I had a NET in the tail of the pancreas. Had a surgery. Doing great since 12/ 2020.
Thank you!
Excellent update, Sir. Stay Blessed
Thank you!
Hi Dr. Kim, just wanted to thank you for these short videos. I'm a medical oncology resident prepping for my exam in a few weeks. These videos provide a great summary for me and helps me know where to dive into more details on. Really appreciate it, wishing you all the best!
Thank you, best for your endeavor in oncology!
The US Food and Drug Administration (FDA) has approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) in combination with oxaliplatin, fluorouracil, and leucovorin for the first-line treatment of metastatic pancreatic adenocarcinoma.
The approval was based on findings from the randomized, controlled, open-label NAPOLI3 trial, which evaluated the combination, known as NALIRIFOX, vs gemcitabine plus nab-paclitaxel in patients who had not previously received chemotherapy in the metastatic setting.
The National Comprehensive Cancer Network also upgraded the regimen as the preferred first-line treatment for metastatic pancreatic adenocarcinoma as well as for locally advanced disease.
clinicaltrials.gov/study/NCT04083235
In the trial, 770 patients were randomized 1:1 to receive NALIRIFOX or gemcitabine plus nab-paclitaxel, a current standard of care in this setting. Patients receiving NALIRIFOX demonstrated significant improvements in median overall survival and progression-free survival (PFS) - with a median overall survival of 11.1 months vs 9.2 months in the gemcitabine plus nab-paclitaxel arm (hazard ratio [HR], 0.84) and a median PFS of 7.4 months vs 5.6 months (HR, 0.70). The overall response rate was also higher in the NALIRIFOX arm - 41.8% vs 36.2%.
The recommended irinotecan liposome dose is 50 mg/m2 administered by intravenous infusion over 90 minutes every 2 weeks, before oxaliplatin, fluorouracil, and leucovorin. There is no recommended irinotecan liposome dose for patients with serum bilirubin above the upper limit of normal.
The label for irinotecan liposome comes with a boxed warning, noting a risk for severe or life-threatening neutropenia and diarrhea.
Nice presentation thank you sir
You’re welcome!
Come back to Hawaii Dr Kim! - your favorite nurse at north Hawaii 😉
Thank you, yes, I will!
Hindi main samjhaie